These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 34112250)

  • 1. Blocking siglec-10
    Xiao N; Zhu X; Li K; Chen Y; Liu X; Xu B; Lei M; Xu J; Sun HC
    Exp Hematol Oncol; 2021 Jun; 10(1):36. PubMed ID: 34112250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer.
    Lv K; Sun M; Fang H; Wang J; Lin C; Liu H; Zhang H; Li H; He H; Gu Y; Li R; Shao F; Xu J
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siglec-9
    Wang Y; He M; Zhang C; Cao K; Zhang G; Yang M; Huang Y; Jiang W; Liu H
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of DC-SIGN
    Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
    Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TREM2
    Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
    J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD1
    Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
    J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas.
    Li B; Guo Y; Yi Y; Huang Z; Ren Y; Wang H; Yang L
    J Transl Med; 2023 Sep; 21(1):599. PubMed ID: 37674198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.
    Xiao R; Tian Y; Zhang J; Li N; Qi M; Liu L; Wang J; Li Z; Zhang J; Zhao F; Wang T; Tan S; Li C; Wu Z; Yu M; Jiang X; Zhan P; Gao L; Han B; Liu X; Liang X; Ma C
    J Hepatol; 2024 May; 80(5):792-804. PubMed ID: 38331327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8
    Zhu CX; Yan K; Chen L; Huang RR; Bian ZH; Wei HR; Gu XM; Zhao YY; Liu MC; Suo CX; Li ZK; Yang ZY; Lu MQ; Hua XF; Li L; Zhao ZB; Sun LC; Zhang HF; Gao P; Lian ZX
    J Hepatol; 2024 May; ():. PubMed ID: 38759889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress.
    Li Z; Duan D; Li L; Peng D; Ming Y; Ni R; Liu Y
    Front Pharmacol; 2024; 15():1382256. PubMed ID: 38957393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD74
    Xiao N; Li K; Zhu X; Xu B; Liu X; Lei M; Sun HC
    Cancer Immunol Immunother; 2022 Jan; 71(1):57-69. PubMed ID: 34009409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
    Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
    Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer.
    Zhang H; Liu Z; Wen H; Guo Y; Xu F; Zhu Q; Yuan W; Luo R; Lu C; Liu R; Gu J; Ge D
    Cancer Immunol Immunother; 2022 Oct; 71(10):2511-2522. PubMed ID: 35278107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.
    Sun G; Liu H; Zhao J; Zhang J; Huang T; Sun G; Zhao S; Zhang Z; Cao H; Rong D; Kong X; Ji Q; Liu L; Wang X; Tang W; Xia Y
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The XOR-IDH3α axis controls macrophage polarization in hepatocellular carcinoma.
    Lu Y; Sun Q; Guan Q; Zhang Z; He Q; He J; Ji Z; Tian W; Xu X; Liu Y; Yin Y; Zheng C; Lian S; Xu B; Wang P; Jiang R; Sun B
    J Hepatol; 2023 Nov; 79(5):1172-1184. PubMed ID: 37473847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
    Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the Tumor Immune Microenvironment Identifies M0 Macrophage-Enriched Cluster as a Poor Prognostic Factor in Hepatocellular Carcinoma.
    Farha M; Jairath NK; Lawrence TS; El Naqa I
    JCO Clin Cancer Inform; 2020 Oct; 4():1002-1013. PubMed ID: 33136432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.